TABLE 6.

Adverse events during the treatment period.

	CHM user	WM user	p-value
	(n = 701)	(n = 659)
The Incidence of Adverse Events—no. (%)
Hypertension	1 (0.1)	18 (2.7)	<0.001
Ischaemic heart disease	0	2 (0.3)	0.055
Cerebrovascular disease	0	0	—
Brain disease	0	0	—
Hypertensive encephalopathy	0	0	—

*The p-value was calculated by Pearson’s chi-squared test and Student’s t-test.